Legal & General Group Plc boosted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1,577.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,682 shares of the biotechnology company's stock after buying an additional 16,628 shares during the quarter. Legal & General Group Plc's holdings in Ascendis Pharma A/S were worth $2,433,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in Ascendis Pharma A/S in the third quarter worth about $30,000. Jones Financial Companies Lllp boosted its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. increased its stake in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares during the period. GAMMA Investing LLC raised its holdings in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $203,000.
Ascendis Pharma A/S Price Performance
NASDAQ ASND traded up $3.86 on Wednesday, hitting $170.44. 377,774 shares of the company were exchanged, compared to its average volume of 489,453. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $171.34. The company's 50 day moving average price is $154.57 and its 200-day moving average price is $139.68. The firm has a market capitalization of $10.39 billion, a P/E ratio of -24.01 and a beta of 0.54.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.
Analysts Set New Price Targets
Several analysts have weighed in on ASND shares. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Royal Bank of Canada began coverage on shares of Ascendis Pharma A/S in a report on Wednesday, April 16th. They issued an "outperform" rating and a $205.00 price objective for the company. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. boosted their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of "Moderate Buy" and a consensus target price of $204.67.
Read Our Latest Report on Ascendis Pharma A/S
Ascendis Pharma A/S Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
